NTT Com Wins Two MEF 3.0 Proof of Concept Awards
21.11.2019 09:03:00 EET | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO: 9432), announced today it received MEF 3.0 Proof of Concept Awards in two categories, “MEF3.0 SD-WAN Implementation 2019” and “Network Slicing Implementation 2019,” during the MEF 3.0 Proof of Concept Showcase event held in the U.S. city of Los Angeles from November 18 to 22.
The showcase was organized by the Metro Ethernet Forum (MEF), a global telecom industry alliance with more than 220 members. NTT Com attended the showcase to introduce an SD-WAN1 service and a 5G-related proof of concept (PoC)2, joining other telecom carriers and manufacturers that presented their own initiatives for judging.
About MEF Awards
https://www.mef.net/2019_MEF_Awards
MEF3.0 SD-WAN Implementation 2019
NTT Com’s orchestrated virtualized multivendor SD-WAN services received the award presented for the best SD-WAN service in compliance with MEF specifications. The NTT Com service was recognized for enabling lifecycle3 management and operation of multiple SD-WAN products with a unified portal and white box CPEs4.
SD-WAN is not a standardized technology, so many unique network devices exist, requiring operation methods to be designed to each manufacturer’s technologies. To solve this problem, NTT Com conducted a PoC to implement unified control of multiple SD-WAN products based on MEF-standardized SD-WAN specifications, data models, interfaces and test methods.
NTT Com collaborated with partner companies to co-develop the orchestrated virtualized multivendor SD-WAN services in conformance with the MEF70 and MEF SD-WAN Presto API standard5. The service uses a universal CPE platform, enabling multiple SD-WAN products to be installed on the white box CPE, and a unified configuration portal, enabling unified control of multiple SD-WAN products.
The partner companies involved in co-development are ADVA, Netcracker Technology, Silver Peak, Spirent Communications, Versa Networks and NEC Corporation.
Network Slicing Implementation 2019
The award for the best network slicing6 technology was presented to NTT Com collaborating with partner companies for its 5G xHaul Sharing Slices with LSO Orchestration, which enables automatic control by using network slices for multiple-operator interconnection.
5G technology is anticipated to be used in companies and local governments in addition to telecom carriers by utilizing to such as private 5G service. The new network system that the various companies can use in common like this is necessary to build the network effectively.
NTT Com collaborated with partner companies to co-develop the shared xHaul architecture in conformance with the MEF standard by utilizing network slicing technology.
The architecture creates end-to-end network slices by multi-operator collaboration to share the access network (xHaul) required for 5G service.
The partner companies that contributed to the solution are NTT Corporation and Okinawa Open Laboratory.
SDN7 and network functions virtualization (NFV)8 technologies continue to be advanced through open-source development projects and by standardization organizations. Going forward, NTT Com aims to help drive the development of SDN and NFV technologies through its participation in MEF and ONF9.
|
1: |
SD-WAN simplifies the management and operation of a WAN by separating the networking hardware from its control mechanism. |
|
2: |
Verification and demonstration of prototype development to demonstrate new concepts, theories, principles and ideas for commercialization and service development |
|
3: |
Service provision process covering application, start of use, settings and quality control |
|
4: |
Separates CPE hardware and software functions and allows software selection and installation for each application |
|
5: |
MEF specification for SD-WAN: https://www.mef.net/resources/technical-specifications/download?id=122&fileid=file1 |
|
6: |
Virtual division of network according to characteristics, such as low latency, wide bandwidth or high reliability, by application purpose |
|
7: |
Technologies that dynamically control network configuration and settings using software |
|
8: |
Method for operating network devices as software on virtualized infrastructure of general-purpose servers |
|
9: |
Open Networking Foundation, which standardizes SDN technologies and develops open source software |
Related links
- Orchestrated Virtualized Multi-Vendor SD-WAN Services
- 5G xHaul Sharing as Slices with LSO Orchestration
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 450,000m2 of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120006059/en/
Contact information
For more information
Ryu Kanishima
Service Strategy Department
NTT Communications
Mail: mgr-nwcore-td@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom